Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer's Record-Breaking $2.3 Bil. Settlement with DoJ Imposes New Restrictions on Corporate Behavior

This article was originally published in The Pink Sheet Daily

Executive Summary

A new corporate integrity agreement requires review of sales rep compensation structure, "needs assessment" of publications.

You may also be interested in...



Pfizer Whistleblower Suit Alleges Sales Reps Had Targets For Rapamune Off-Label Uses

Former Wyeth sales reps also allege they were trained to avoid FDA personnel at medical meetings.

Pfizer Whistleblower Suit Alleges Sales Reps Had Targets For Rapamune Off-Label Uses

Former Wyeth sales reps also allege they were trained to avoid FDA personnel at medical meetings.

Pfizer Research Grant Recipient Charged With Falsifying Study Results

Department of Justice alleges that Massachusetts anesthesiologist Scott Rueben published fake results of studies he never conducted.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS069999

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel